Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 14/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266762 | 0.86 | CYP17A1 (0.42) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5753882 | 0.83 | CYP3A4 (0.44) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5752256 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5751835 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4027994 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4026634 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5750907 | 0.81 | CYP3A4 (0.44) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5752772 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5749713 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5752145 | 0.80 | CYP3A4 (0.42) | CYP3A4CYP17A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222174-B1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA PHARMACEUTICAL (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-6649643-B1 | Antitumor, anticarcinogenic, and antimetastasis agents; benign prostatic hyperplasia, alopecia, endometriosis, uterine myoma, hirsutism, virilism, precocious puberty, mastopathy, and polycystic overay syndrome treatment | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-18 | — | — | US | disclosed |